Glenmark launches this anti-diabetic drug in India, know price, it will reduce the cost of treatment by almost 70%

The drug is being marketed under the brand name Lirafit.  India TV Money
Photo: Reuters The drug is being marketed under the brand name Lirafit.

Drugmaker Glenmark Pharmaceuticals on Wednesday launched a biosimilar of popular anti-diabetic drug liraglutide in India. The drug is being marketed as Lirafit after receiving approval from the Drug Controller General of India (DCGI), the company said in a statement. According to PTI News, the price of 1 standard dose of Lyraft drug is around Rs.100.

It will reduce the cost of treatment by about 70%.

According to the news, the company claims that 2 mg (daily) will reduce the cost of treatment by about 70%. Lirafit will be available by prescription only. Alok Malik, Chairman and Business Head, India Formulations, Glenmark Pharmaceuticals, said that diagnostic trials have shown that it is effective in improving glycemic control in adults with atherosclerotic cardiovascular disease (ASCVD) and obesity as well as type 2 diabetes. Helps improve control.

An effective treatment option

Malik said liraglutide has shown positive cardiovascular and renal safety results in patients in clinical trials, making it an effective treatment option for patients with type 2 diabetes. “With this launch, we have now taken another important step in the field of diabetes treatment and entered the injectable anti-diabetic market,” Malik said.

Every investor in Glenmark Pharmaceuticals Limited should be aware of the most powerful shareholder groups. The group with the largest stake in the company, at around 47 percent, are private companies. In other words, the group faces maximum downside risk. Institutions are 32% shareholders of the company. Institutions often own shares in more established companies, while it is not uncommon for insiders to own shares in smaller companies as well.

Latest business news.

Leave a Comment